Crossmark

A targetable ‘rogue’ neutrophil-subset, [CD11b+DEspR+] immunotype, is associated with severity and mortality in acute respiratory distress syndrome (ARDS) and COVID-19-ARDS

Crossref DOI link: https://doi.org/10.1038/s41598-022-09343-1

Published Online: 2022-04-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Herrera, Victoria L. M.

Walkey, Allan J.

Nguyen, Mai Q.

Gromisch, Christopher M.

Mosaddhegi, Julie Z.

Gromisch, Matthew S.

Jundi, Bakr

Lukassen, Soeren

Carstensen, Saskia

Denis, Ridiane

Belkina, Anna C.

Baron, Rebecca M.

Pinilla-Vera, Mayra

Mueller, Meike

Kimberly, W. Taylor

Goldstein, Joshua N.

Lehmann, Irina

Shih, Angela R.

Eils, Roland

Levy, Bruce D.

Ruiz-Opazo, Nelson
Funding

Funding for this research was provided by:

Boston Biomedical Innovation Center (NIH 1UL1TR001430)

Clinical and Translational Science Institute, Boston University (NIH 1UL1TR001430)

Office of Technology Development, Boston University (Ignition Award)
License Information

Text and Data Mining valid from 2022-04-04

Version of Record valid from 2022-04-04
More Information

Article History

Received: 25 August 2021

Accepted: 7 March 2022

First Online: 4 April 2022

Competing interests

: Boston University holds awarded and pending patents on DEspR. VLMH and NRO are co-inventors filed by Boston University. These patents comprise the option granted for exclusive license to NControl Therapeutics, Inc. VLMH, NRO are scientific co-founders of NControl Therapeutics, and paid consultants with equity in NControl Therapeutics, Inc. NControl Therapeutics was not involved in the design, conception, data interpretation, or manuscript preparation. All other co-authors have no competing interests. JNG: Consultant for NControl, Cayuga, CSL Behring, Alexion, Pfizer, Takeda. RMB: Member of Advisory Boards for Merck and Genentech.

Document is current

Any future updates will be listed below